AUPH
Aurinia·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AUPH
Aurinia Pharmaceuticals Inc.
A commercial-stage biopharmaceutical company
#140, 14315 - 118 Avenue, Edmonton, Alberta, T5L 4S6
--
Aurinia Pharmaceuticals Inc. (Alberta, Canada) is organized under the Business Corporations Act. Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on providing therapies to treat target patient groups with unmet medical needs affected by autoimmune, renal and rare diseases. In January 2021, Aurinia Pharma launched the first FDA-approved oral drug LUPKYNIS (voclosporin) for the treatment of adult patients with active LN. LUPKYNIS is an oral CNI immunosuppressant that has been shown to improve near- and long-term outcomes of LN when used in combination with mycophenolate mofetil (MMF) (although MMF is not currently approved) and steroids. By inhibiting calcineurin, LUPKYNIS reduces cytokine activation, blocks interleukin IL-2 expression and T cell-mediated immune response. LUPKYNIS may also stabilize podocytes, thereby preventing proteinuria.
Earnings Call
Q1/2025
Estimate EPS0.1
Actual EPS0.16
Estimate Revenue61.06M
Actual Revenue62.50M
Aurinia's Q1 2025 Earnings Call: Unraveling Contradictions in LUPKYNIS Sales and AUR200 Strategy
May 20,2025 07:09
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.14
Actual EPS0.16
Estimate Revenue64.27M
Actual Revenue70.00M
Contradictions in LUPKYNIS and AUR200: Insights from the Latest Earnings Call
Jul 31,2025 06:03
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AUPH has released its 2025 Q3 earnings. EPS was reported at 0.23, versus the expected 0.16, beating expectations. The chart below visualizes how AUPH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AUPH has released its 2025 Q3 earnings report, with revenue of 73.47M, reflecting a YoY change of 8.41%, and net profit of 31.55M, showing a YoY change of 119.87%. The Sankey diagram below clearly presents AUPH's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
